Acoramidis (AG10) is currently being studied in a Phase 3 clinical trial in patients with ATTR-CM (ATTRibute-CM) and a Phase 3 clinical trial in patients with ATTR-PN (ATTRibute-PN).
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the growing unmet need in diseases caused by transthyretin amyloidosis, or ATTR. ATTR is caused by the destabilization of TTR due to inherited mutations or aging and is commonly divided into 3 distinct categories: wild-type ATTR cardiomyopathy (wtATTR-CM), variant ATTR cardiomyopathy (vATTR-CM), and ATTR polyneuropathy (ATTR-PN). The estimated worldwide prevalence of each condition is 400,000 patients, 40,000 patients, and 10,000 patients, respectively. Progression of all forms of ATTR causes significant morbidity, impacts productivity and quality of life, and creates a significant economic burden due to the costs associated with progressively greater patient needs for supportive care. We seek to treat this well-defined family of diseases at their collective source by stabilizing transthyretin.
Eidos is led by a team of highly experienced clinical researchers, physicians, and scientists who are responsible for developing more than 30 molecules through IND applications and more than 10 approved drugs. Together with patients and physicians, we aim to develop a safe, effective, and disease-modifying treatment for ATTR patients as expeditiously as possible.
EMA=European Medicines Agency; FDA=Food and Drug Administration; IND=Investigational New Drug; ODD=orphan drug designation.
The safety and efficacy of acoramidis (AG10) have not been established. There is no guarantee that acoramidis (AG10) will receive health authority approval or become commercially available in any country for the uses being investigated.